Skip to content
PulseMS
Log inJoin
Research & community

MS research, together.

MS research in plain English. Perspectives from people who understand.

Research evidence filters

Filters apply to reviewed research. Unknown dates and unassessed posts are excluded when a corresponding filter is active.

Reset filters
Topics & sourcesFiltered
Research and community updates, newest first.#NeuroprotectionAI researchClear filters
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyNot reportedTrial registry

Effects of Body Brain Trainer Software on Cognitive Deficits in People with MS

A study is assessing how the Body Brain Trainer (BBT) software, an exergame, influences cognitive deficits compared to RehaCom software in people with MS, over four weeks. Previous evaluations support its feasibility and safety for this group.

What this does not proveNo results are currently available, and the study's design does not provide information on specific outcomes or efficacy of the interventions.
#Neuroprotection
View abstract on PubMedAI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyNot reportedTrial registry

Effects of the MIND Diet on Neurofilament Light Chain in Human Subjects

In a currently recruiting study, participants with Multiple Sclerosis will be randomly assigned to follow the MIND diet for one year or maintain their current diet. The primary outcome measured will be changes in plasma neurofilament light chain (NfL), a potential biomarker for neurodegeneration.

What this does not proveNo results are available yet as the trial is ongoing and has not completed. The primary completion date is estimated, and findings have not been posted to assess efficacy.
#Neuroprotection
View abstract on PubMedAI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedSubjects not reportedSystematic reviewPeer review unconfirmed

Ferroptosis in Neurodegenerative Diseases (Animal/Cell Studies)

This systematic review discusses how ferroptosis is connected to neurodegenerative diseases, including Multiple Sclerosis, highlighting the role of iron metabolism disruptions and oxidative stress. It suggests that therapies like radical-trapping antioxidants and iron chelators show potential in targeting ferroptosis.

What this does not proveThe review does not provide direct experimental results or clinical trial outcomes, meaning it does not confirm any therapies' efficacy in humans.
#Neuroprotection
View abstract on PubMedPMID 42770359AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyObservationalPeer review unconfirmed

Human Subjects with Multiple Sclerosis: Energy Cost of Walking and Dynamic Balance

In a study with 20 people with multiple sclerosis, it was found that walking at comfortable speeds had an energy cost of 4.99 J/kg/m while fast walking cost 4.84 J/kg/m. Poor dynamic balance was linked to higher energy costs, especially at slower walking speeds.

What this does not proveThe study design was cross-sectional, which limits the ability to draw causal conclusions about the relationship between dynamic balance and energy costs.
#Neuroprotection
View abstract on PubMedPMID 42757673AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedSubjects not reportedSystematic reviewPeer review unconfirmed

Neuroprotective Activity of Curcumin in Animal Models

A systematic review found that curcumin showed neuroprotective activity in preclinical models of Alzheimer's, Parkinson's, multiple sclerosis, and amyotrophic lateral sclerosis. However, over 80% of positive findings from animal studies have not been replicated in humans.

What this does not proveThe findings are limited by incomplete formulation characterization, lack of CNS-exposure biomarkers in trials, and significant discrepancies between animal and human studies.
#Curcumin#DrugDeliverySystems#Neuroprotection#SymptomMgmtRelevant to Neurologist, Pharmacologist
View abstract on PubMedPMID 42797450AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studySystematic reviewPeer review unconfirmed

Role of Cytokines and MMPs in Multiple Sclerosis Pathogenesis

A systematic review identified key cytokines (like IL-3, IL-5, IL-6, and MMPs) as critical drivers of neuroinflammation and neurodegeneration in multiple sclerosis (MS). MMP-1 could differentiate early MS from clinically isolated syndrome, while IL-9, IL-10, and IL-13 may be targets for neuroprotective strategies.

What this does not proveThe findings do not confirm any treatment effectiveness and lack clinical trial data for validation.
#Biomarkers#Cytokines#Immunomodulation#NeuroprotectionRelevant to Neurologist, Immunologist
View abstract on PubMedPMID 42794509AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedSubjects not reportedSystematic reviewPeer review unconfirmed

Cannabidiol (CBD) and Its Neuroprotective Effects in Animal Models of Multiple Sclerosis and Other Neurodegenerative Diseases

CBD demonstrates anti-inflammatory, antioxidant, mitochondria-protective, and neuroprotective properties in preclinical models related to multiple sclerosis and other neurodegenerative diseases. Clinical evidence, however, primarily addresses symptoms like agitation and sleep disturbances without proving disease modification.

What this does not proveThe clinical evidence remains preliminary and does not show proven disease modification. Key barriers include inconsistent bioavailability and insufficient understanding of exposure-response relationships.
#CBD#Neuroprotection#SymptomMgmt#WellnessRelevant to Neurologist, Pharmacologist
View abstract on PubMedPMID 42790169AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedSubjects not reportedSystematic reviewPeer review unconfirmed

Stem Cell Therapies for Demyelinating Diseases: Systematic Review

A systematic review found that autologous hematopoietic stem cell transplantation (AHSCT) is the most supported therapy for highly active relapsing MS, primarily aiding through immune system reconstitution. In contrast, mesenchymal stromal cell (MSC) methods remain investigational due to unresolved efficacy and safety issues, while avenues such as MSC-derived extracellular vesicles and iPSC-derived products are still in preclinical stages.

What this does not proveThe review does not provide specific clinical trial results, and numerous factors, such as product heterogeneity and safety concerns, limit the translation of these therapies into clinical practice.
#StemCellTherapy#DMTs#ImmuneReconstitution#NeuroprotectionRelevant to Neurologist, Immunologist
View abstract on PubMedPMID 42789490AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studySystematic reviewPeer-reviewed

Human studies on α7-nAChR activation in MS

A systematic review indicates that activation of the α7-nAChR may lead to reduced inflammation and support nerve resilience in the central nervous system (CNS).

What this does not proveHowever, there are challenges to translating these findings into clinical practice, such as receptor desensitization and the absence of validated biomarkers.
#Immunomodulation#Neuroprotection#DMTsRelevant to Neurologist, Immunologist
View abstract on PubMedPMID 42790772AI summary of a published abstract. Not medical advice.